NRSN (NeuroSense Therapeutics) 3-Year Book Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.38
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics 3-Year Book Growth Rate?

NeuroSense Therapeutics NRSN +7.39% 31 3-Year Book Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,132 Biotechnology companies, NeuroSense Therapeutics ranks worse than 88339.13% on this metric.

NeuroSense Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $-0.05.

During the past 12 months, NeuroSense Therapeutics's average Book Value per Share Growth Rate was -143.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of NeuroSense Therapeutics was 77.70% per year. The lowest was -48.70% per year. And the median was 14.50% per year.

NeuroSense Therapeutics  (NAS:NRSN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

NeuroSense Therapeutics 3-Year Book Growth Rate Related Terms

NRSN vs CELU, GRDX, ZIVO: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's 3-Year Book Growth Rate falls into.


NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
NeuroSense Therapeutics (NRSN) has a 3-Year Book Growth Rate of 0.00% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 1132 companies in the Biotechnology industry.
Is NeuroSense Therapeutics' 3-Year Book Growth Rate too high?
NeuroSense Therapeutics' current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, NeuroSense Therapeutics ranks #999999 out of 1132 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' 3-Year Book Growth Rate compare to CELU and GRDX?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 1132 companies for 3-Year Book Growth Rate. This places NeuroSense Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current 3-Year Book Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price